PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.82%
R&D growth while TRAW reduces spending. John Neff would investigate strategic advantage.
-13.19%
G&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-2.45%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-2.45%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
D&A reduction while TRAW shows 1.03% growth. Joel Greenblatt would examine efficiency.
-13.13%
EBITDA decline while TRAW shows 10.14% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Operating income growth below 50% of TRAW's 10.27%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
49.45%
Other expenses growth above 1.5x TRAW's 26.32%. Michael Burry would check for concerning trends.
10.71%
Similar pre-tax income growth to TRAW's 10.29%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.71%
Similar net income growth to TRAW's 10.12%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
23.59%
EPS growth exceeding 1.5x TRAW's 10.14%. David Dodd would verify competitive advantages.
23.59%
Diluted EPS growth exceeding 1.5x TRAW's 10.14%. David Dodd would verify competitive advantages.
16.70%
Share count reduction below 50% of TRAW's 0.02%. Michael Burry would check for concerns.
16.70%
Diluted share reduction below 50% of TRAW's 0.02%. Michael Burry would check for concerns.